Menu Hover News Today

Cilta-cel is a BCMA-directed and genetically modified autologous T-cell immunotherapy that involves reprogramming a patient’s own T-cells with a transgene encoding a chimeric antigen receptor (CAR), which detects

Vistagen has signed a definitive agreement for the acquisition of clinical-stage drug development firm Pherin Pharmaceuticals.

The US FDA has granted fast track designation (FTD) for Kintara Therapeutics’ REM-001, to treat cutaneous metastatic breast cancer (CMBC).

The regulatory authorities in Taiwan and South Korea have granted fast-tracked approval process for Everest Medicines’ Nefecon.

ViiV Healthcare and the Medicines Patent Pool (MPP) have entered into a voluntary licensing agreement to expand access to cabotegravir

SRI and Amylyx have joined forces to develop new drug candidates to treat amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.

Mogrify has collaborated with Astellas Pharma to conduct research on in vivo regenerative medicine approaches to address sensorineural hearing loss.

Gerresheimer has significantly ramped up its glass and plastic production capacities in India. A new modern plant to produce high quality plastic containers and closures was built at

ViGeneron, a Germany-based gene therapy company, has entered a target-specific strategic collaboration and option agreement with Regeneron Pharmaceuticals.

Bristol Myers Squibb has obtained approval from the US FDA for Opdualag to treat unresectable or metastatic melanoma patients.